HIV drug nevirapine (Viramune): risk of severe hepatotoxicity

Wooltorton, Eric
March 2004
CMAJ: Canadian Medical Association Journal;3/30/2004, Vol. 170 Issue 7, p1091
Academic Journal
Focuses on the hepatotoxic effects of the HIV drug, nevirapine. Effect of nevirapine on asparate aminotransferase; Occurrence of symptomatic hepatitis in patients treated with the drug; Disadvantage of using the drug for multi dose post-exposure prophylaxis.


Related Articles

  • Case Report: Aminotransferase Elevation in HIV/Hepatitis B Virus Co-infected Patients Treated with Two Active Hepatitis B Virus Drugs. Jain, Mamta K.; Parekh, Nimisha K.; Hester, Jill; Lee, William M. // AIDS Patient Care & STDs;Dec2006, Vol. 20 Issue 12, p817 

    Discerning drug hepatotoxicity from viral hepatitis flares remains an ongoing problem unique to patients coinfected with HIV and hepatitis B (HBV). We present three such coinfected patients who have been on two anti-HBV agents, lamivudine and tenofovir disoproxil fumarate simultaneously, as part...

  • HIV/HCV coinfection ups risk of liver toxicity during HAART.  // Reactions Weekly;5/8/2010, Issue 1300, p2 

    The article offers information on a prospective, observational study, which indicated that coinfection with human immunodeficiency virus (HIV)/hepatitis C virus (HCV) lead to increased liver enzyme elevations compared with HIV-monoinfected patients.

  • Severe Hepatotoxicity Associated with Nevirapine Use in HIV-Infected Subjects. Sanne, Ian; Mommeja-marin, Herve; Hinkle, John; Bartlett, John A.; Lederman, Michael M.; Maartens, Gary; Wakeford, Charles; Shaw, Audrey; Quinn, Joseph; Gish, Robert G.; Rousseau, Franck // Journal of Infectious Diseases;3/15/2005, Vol. 191 Issue 6, p825 

    Human immunodeficiency virus (HIV)-infected South African patients (n = 468) received blinded lamivudine or emtricita- bine, stavudine, and either nevirapine or efavirenz (based on screening viral load). Baseline characteristics were analyzed in univariate and multivariate regression, to...

  • Drug-Induced Liver Injury. Kaplowitz, Neil // Clinical Infectious Diseases;3/1/2004 Supplement, Vol. 38, pS44 

    Drug-induced hepatotoxicity is a frequent cause of liver injury. The predominant clinical presentation is acute hepatitis and/or cholestasis, although almost any clinical pathological pattern of acute or chronic liver disease can occur. The pathogenesis of drug-induced liver disease usually...

  • General Concepts of Drug Induced Liver Injury. Sharma, Sumeet; Anand, Gaurav; Arora, Tarun // International Journal of Research in Pharmacy & Science;Jul2011, Vol. 1 Issue 2, p18 

    Drug-induced liver injury (DILI) is a problem of increasing significance, but has been a long-standing concern in the treatment of tuberculosis (TB) infection. The liver has a central role in drug metabolism and detoxification, and is consequently vulnerable to injury. The pathogenesis and types...

  • Can HCV affect the efficacy of anti-HIV treatment? Filippini, P.; Coppola, N.; Scolastico, C.; Liorre, G.; Nocera, R.; Sagnelli, E.; Piccinino, F. // Archives of Virology;May2000, Vol. 145 Issue 5, p937 

    Summary. To evaluate the impact of new antiretroviral combinations (HAART: Highly Active Anti Retroviral Therapy) on HCV replication and liver enzyme levels, we analysed the changes in HCV viremia and aminotransferase levels in HIV and HCV co-infected patients. Moreover, to evaluate the...

  • No relationship between high nevirapine plasma concentration and hepatotoxicity in HIV-1-infected patients naive of antiretroviral treatment or switched from protease inhibitors. Dailly, Eric; Billaud, Eric; Reliquet, Véronique; Breurec, Sébastien; Perré, Philippe; Léautez, Sophie; Jolliet, Pascale; Bourin, Michel; Raffi, François // European Journal of Clinical Pharmacology;Jul2004, Vol. 60 Issue 5, p343 

    Objective. A prospective population pharmacokinetic study of nevirapine (NVP) was performed to test the relationship between hepatotoxicity and NVP trough plasma concentration and to identify which covariates could influence NVP pharmacokinetics. Methods. All patients [77 HIV-1 (human...

  • Saskatchewan Agrees to Cover New HCV and HIV Drugs. Procyk, Roger // Canadian HIV/AIDS Policy & Law Review;Aug2003, Vol. 8 Issue 2, p28 

    Reports on the agreement of the Saskatchewan government to cover the new hepatitis C virus and HIV drugs Pegetron and Valcyte as of August 2003. Terms under the Exceptional Drug Status program; Criterion for obtaining special support status; Information on the drugs.

  • Sexual transmission of hepatitis C virus and its relation with hepatitis B virus and HIV. Tor, J.; Libre, J.M.; Carbonell, M.; Muga, R.; Ribera, A.; Soriano, V.; Clotet, B.; Sabria, M.; Foz, M. // BMJ: British Medical Journal (International Edition);11/17/90, Vol. 301 Issue 6761, p1130 

    Determines the extent of transmission of hepatitis C virus in sexual partners of intravenous drug users in Barcelona, Spain. Prevalence of HIV, hepatitis B virus, and hepatitis C virus infections in homosexual men; Collection of serum samples by enzyme immune analysis; Risk of acquiring...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics